AddedRisk Factors
ZURZUVAE is the first oral treatment specifically indicated for adults with PPD. ZURZUVAE may not achieve, or, even if achieved, maintain, broad market acceptance. Healthcare professionals may decide not to use ZURZUVAE as a treatment option for their patients with PPD or may only consider prescribing ZURZUVAE for a subset of women with PPD in their practice who they consider to have particularly severe symptoms relative to other patients suffering from this disease. ZURZUVAE also may not achieve or, even if achieved, maintain broad market acceptance among women with PPD who may decide that they do not want to be treated with ZURZUVAE, including due to concern about the safety and tolerability profile of ZURZUVAE or use of ZURZUVAE while breastfeeding. ZURZUVAE includes a boxed warning that instructs healthcare professionals to advise patients that ZURZUVAE causes driving impairment due to central nervous system depressant effects, and that people who take ZURZUVAE should not drive a motor vehicle or engage in other potentially hazardous activities requiring complete mental alertness until at least 12 hours after ZURZUVAE administration for the duration of the once-daily, 14-day treatment course, which could decrease willingness to prescribe or use ZURZUVAE. The label also includes information about adverse events and other warnings and precautions that may cause a woman with PPD not to consider ZURZUVAE as a treatment option.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
ZURZUVAE also may not achieve or, even if achieved, maintain broad market acceptance for the treatment of women with PPD if payors are not willing to cover and provide reimbursement for the treatment or impose significant restrictions on reimbursement. Payors that currently have favorable coverage for ZURZUVAE for the treatment of women with PPD may decide to change their policies and limit coverage or reimbursement for ZURZUVAE, including by requiring women with PPD to try other treatments prior to ZURZUVAE, requiring a specific showing of symptom severity with the use of measurement scales, requiring prior consultation with a psychiatrist or other specialist, or imposing other onerous prior authorization requirements, or they may deny coverage or reimbursement for other reasons or in all cases. Some payors currently require that healthcare professionals attest that the women with PPD for whom they have prescribed ZURZUVAE have severe symptoms. In addition, even if a healthcare professional writes a prescription for ZURZUVAE for the treatment of a woman with PPD, the prescription may not result in product being shipped to the patient and/or the patient taking ZURZUVAE. The healthcare professional or the patient may, for example, not take the steps necessary to obtain reimbursement or to have the prescription filled at the specialty pharmacy or may find the process of obtaining a prescription through the specialty pharmacy too slow or complicated. There is no guarantee that the infrastructure, systems, processes, policies, relationships or materials we and Biogen have built for the commercialization of ZURZUVAE for the treatment of women with PPD in the U.S. will be sufficient for us to achieve or, even if achieved, maintain success.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
Our commercialization of ZURZUVAE in PPD may be negatively impacted by competition from other drugs currently on the market or that may be approved in the future. The number of women with PPD, the unmet need for additional treatment options for women with PPD, and the potential market for ZURZUVAE may be significantly smaller than we expect, or we and Biogen may encounter other market-related issues in the commercialization of ZURZUVAE for the treatment of women with PPD, including as a result of the price we charge. We and our collaboration partner, Biogen, may not be applying the optimal resources to the launch of ZURZUVAE or we or Biogen may not be able or willing to scale our resources at the right time or at an effective level.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedRisk Factors
During 2025 several Executive Orders were issued by the President of the United States, which generally aim to lower the price paid for certain pharmaceutical products in the United States. Aspects of these orders direct the Secretary of Health and Human Services to develop implementation plans and to issue related regulations.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedRisk Factors
the "Business" section of this report, sales of a generic version of Trokendi XR® and Oxteller XR® began in January 2023 and September 2024, respectively. Those competitive products have significantly impacted the sales of Trokendi XR and Oxtellar XR, resulting in an adverse impact on our revenue and profit. In addition, our revenue and profit could be significantly impacted by the timing and rate of commercial acceptance of key new products.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection (formerly SPN-830), as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. See Item 1. Business for further information.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
working toward meeting these post-marketing commitments for Qelbree in a timely manner. We also have post-marketing commitment to conduct a new leachable study for ONAPGO, which was approved by the FDA in February 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
We also have agreements with leading CMOs to manufacture other commercial products and the API for such products. These CMOs offer a comprehensive range of contract manufacturing services.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
We have a license agreement with United Therapeutics Corporation to use one of our proprietary technologies in an oral formulation of treprostinil diethanolamine, or treprostinil, for the treatment of pulmonary arterial hypertension and for other indications. The Company is eligible to receive, and has received royalties under this agreement based on net product sales of United Therapeutics Corporation's product, Orenitram (treprostinil). We are entitled to receive milestones and royalties for the use of this formulation in indications other than arterial hypertension.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type is currently marketed by Allergan plc under an exclusive license agreement between Adamas Pharmaceuticals, LLC and Forest Laboratories Holdings Limited ("Forest"), an indirect, wholly-owned subsidiary of Allergan plc (collectively, "Allergan") in the United States. Adamas Pharmaceuticals LLC receives royalties on net sales of Namzaric.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
In February 2025, the FDA approved ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
In March 2010, a comprehensive change to the U.S. healthcare system, known as the Patient Protection and Affordable Care Act of 2010 (ACA) was enacted, as amended by the Health Care and Education Reconciliation Act of 2010. These laws and their regulations (collectively "HealthCare Reform Law") have far reaching consequences for pharmaceutical companies like the Company. Possible revisions to the HealthCare Reform Law are the subject of continuing legislative debates and litigation.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
The HealthCare Reform Law exerts downward pressure on pharmaceutical pricing, especially under the Medicare and Medicaid programs, and has increased the industry's regulatory burden and operating costs. Among the provisions of the HealthCare Reform Law of importance to the Company's products and product candidates are the following:
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
•An annual, nondeductible fee payable to the U.S. federal government by any entity that manufactures or imports specified branded prescription drugs or biologic agents. This fee is based on each company's market share of prior year total sales of branded products to certain federal healthcare programs;
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
•An increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedRisk Factors
•Rebates owed by manufacturers under the Medicaid Drug Rebate Program (MDRP) for drugs that are inhaled, infused, instilled, implanted, or injected. During 2020, the Centers for Medicare & Medicaid Services (CMS) issued a Final Rule that makes significant modifications to the Medicaid Drug Rebate Program regulations in several areas, including with respect to the treatment of value-based purchasing arrangements, the definition of key terms, and the price reporting treatment of manufacturer-sponsored patient benefit programs. On May 26, 2023, CMS issued a proposed rule seeking to implement policies in the MDRP related to the new legislative requirements in the Medicaid Services Investment and Accountability Act of 2019 to address, among other things, drug misclassification and drug pricing and product data misreporting by manufacturers
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedRisk Factors
Security breaches and other disruptions could compromise our information and expose us to liability which would cause our business and reputation to suffer. 53 • Compliance with the terms and conditions of our Corporate Integrity Agreement requires significant resources and management time and, if we fail to comply, we could be subject to penalties or, under certain circumstances, excluded from government healthcare programs, which would materially adversely affect our business. 56 Risks Related to Our Finances and Capital Requirements • Tariffs may increase our costs. 62 • Our operating results may fluctuate significantly. 56 62 • Our ability to use our net operating loss carryforwards and other tax attributes may be limited or may expire prior to utilization. 57 63 • We have and may further expand our business through acquisitions of new product lines or businesses, which expose us to various risks, including difficulties in integrating acquisitions.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we fail to comply with our obligations under any of these arrangements, we could lose the benefit of such collaborative relationships, including licenses or intellectual property rights. 39 45 • Our failure to successfully develop and market our product candidates would impair our ability to grow. 40 47 • Our clinical trials for our product candidates may fail to demonstrate acceptable levels of safety, efficacy, or other requirements, which could prevent or significantly delay regulatory approval. 41 48 • Delays or failures in the completion of clinical development of our product candidates would increase our costs, delay, or limit our ability to generate revenues. 42 48 • Healthcare reform measures could hinder or prevent the commercial success of our products or product candidates. 44 50 • Healthcare cost containment legislation and the failure of third-party payors to provide appropriate levels of coverage and reimbursement for the use of products and treatments facilitated by our products could harm our business and prospects. 46 52 • Any failure to comply with healthcare regulations, including implementation of any change in compliance with healthcare regulations and laws could cause us to incur significant compliance expenses and any failure to comply could subject us to substantial penalties and fines.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
As evidenced by the passage of the American Rescue Plan Act of 2021 and Inflation Reduction Act of 2022, discussed in greater detail below, and the President's Executive Orders in 2025, we expect these challenges to continue and to potentially intensify during 2025, 2026, as political pressures mount, and healthcare payors, including government-controlled health authorities, insurance companies, and managed care organizations, step up initiatives to reduce the overall cost of healthcare, restrict access to higher-priced new medicines, increase the use of generic products and impose overall price cuts.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Although historically we have been granted FDA orphan drug designation under the Orphan Drug Designation Act for SPN-817 for the treatment of Dravet Syndrome certain drug products and Lennox-Gaustaut Syndrome and for ONAPGO for the treatment of motor fluctuations in adults with advanced PD, product candidates, and we intend to expand our designation for alternative uses where applicable, we may not receive the benefits associated with Orphan Drug Designation.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any limitation may result in the expiration of a portion of the net operating loss or tax credit carryforwards before utilization, which would reduce our gross deferred income tax assets. assets, or may result in limitations in the amount of deductions that could be applied to taxable income, which would increase our current tax provision.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we materially breach these obligations, The termination of if third parties fail to adequately perform their respective obligations, these arrangements could be terminated which those agreements could result in our inability to develop, manufacture, market and sell products that are covered by such intellectual properties.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
If generics or other versions of our products products, including but not limited to generics containing one or more of the active pharmaceutical ingredients present in our products are approved and successfully commercialized, or if products are developed, approved and successfully commercialized which provide similar benefits of treatment for patients, our business could be materially harmed.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
In the future, the potential inability to obtain sufficient product liability insurance at an acceptable cost, or at all, to protect against potential product liability claims could prevent or inhibit the development and commercialization of the pharmaceutical products we develop.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Our ability to utilize our U.S. federal and state net operating losses is and other tax attributes are currently limited and may be limited further, under Sections 382 various sections of the Internal Revenue Code. Code of 1986, as amended (Code) such as Section 382 and Section 383.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
If and to the requirement extent the immediate expensing for domestic research and experimental expenditures is not deferred, repealed or any of the capitalization and amortization requirements reenacted or otherwise modified, it may increase our cash taxes and effective tax rate.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
Certain provisions of the HealthCare Reform Law have not been fully interpreted by the regulatory authorities or the courts and certain provisions are subject to a variety of interpretations, which may complicate the Company's compliance with the HealthCare Laws.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we materially breach these obligations, of if third parties fail to adequately perform their respective obligations, these arrangements could be terminated which could result in our inability to develop, manufacture, market and sell products that are covered by such intellectual properties. terminated.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Third parties have, and in the future may, receive approval to manufacture and market their own products, including but not limited to generics containing apomorphine hydrochloride, for the treatment of Parkinson’s Disease in the U.S.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
In addition to competition for our current commercial products, we anticipate that we will face intense competition when if our pipeline product candidates are approved by regulatory authorities and begin their commercialization process.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Notwithstanding, However, physicians may nevertheless prescribe products to their patients in a manner that is inconsistent with the approved label, which is known as "off label use".
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any penalties, damages, fines, curtailment or restructuring of the Company's operations could adversely affect its ability to operate its business and could impair its financial results.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
Quiet changesRisk Factors
Any impairment in the value of our intangible assets, including goodwill, would could negatively affect our operating results and total capitalization.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
On July 31, 2025, the Company completed its previously announced acquisition of Sage when Saphire, Inc., a Delaware corporation and wholly owned subsidiary of the Company (Purchaser), was merged with and into Sage (the Merger), with Sage continuing as the surviving corporation in the Merger as a wholly owned subsidiary of the Company (the Sage Acquisition). At the time of the Sage Acquisition, Sage had an established commercial product in its portfolio, ZURZUVAE.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
Following the Sage Acquisition, during the third quarter of 2025, Sage Therapeutics, Inc. was reorganized into Sage Therapeutics, LLC.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
•ZURZUVAE® (zuranolone) capsules are the first and only FDA approved oral medicine indicated for the treatment of PPD in adults. ZURZUVAE is a neuroactive steroid that is a positive allosteric modulator of GABAA receptors, targeting
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
both synaptic and extrasynaptic GABAA receptors, and is the first oral, once-daily, 14-day treatment specifically indicated for adults with PPD. ZURZUVAE became commercially available in the U.S. in December 2023 as a treatment option for women with PPD. We and our collaboration partner, Biogen, are jointly commercializing ZURZUVAE in the U.S. under a collaboration agreement (Biogen Collaboration Agreement). The Company and Biogen equally share in all operating profits and losses arising from sales of ZURZUVAE in the U.S., with Biogen recording such product sales.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
SPN-820 is a novel, first in class, intracellular enhancer of mechanistic target of rapamycin complex 1 (mTORC1) signaling. Depression is associated with synapse loss and reduced synaptic plasticity in key brain regions including the prefrontal cortex and increasing mTORC1-mediated synaptic plasticity is a potential avenue to treat depression and associated symptoms. SPN-820 selectively binds to intracellular sestrin proteins and subsequently engages a cascade of multi-protein complexes, enhancing mTORC1 signaling. The intracellular mechanism and the lack of binding to cell surface receptors suggests the potential for a differentiated safety profile and is unlikely to have abuse potential.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The Company initiated a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with MDD. The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The Company has granted Biogen sole rights to develop and commercialize zuranolone outside the U.S., other than in Japan, Taiwan and South Korea where it has granted those rights to Shionogi & Co., Ltd. (Shionogi). Shionogi is currently developing zuranolone for the treatment of patients with MDD in Japan, and in the third quarter of 2024, Shionogi reported that it submitted a new drug application (NDA) in Japan for zuranolone for the treatment of MDD. In the third quarter of 2025, Biogen received approval for zuranolone for the treatment of PPD by the European Medicines Agency (EMA) and Medicines Healthcare Regulatory Agency (MHRA) in Europe and the United Kingdom (U.K.) respectively. In the fourth quarter of 2025, zuranolone received Health Canada Authorization in Canada for treatment indicated for adults with PPD. Also in the fourth quarter of 2025, Shionogi received approval for a product containing zuranolone for the treatment of MDD by the Pharmaceuticals and Medical Devices Agency in Japan. No product containing zuranolone is approved for the treatment of MDD in the United States.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
•The Company initiated a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with MDD. The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
•The Company expects to initiate a Phase 1 single-ascending/multiple-ascending dose study in adult healthy volunteers in the second half of 2026.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The Company completed the Sage Acquisition on July 31, 2025. The transaction was accounted for as a business combination.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
The acquisition method of accounting requires that we recognize the assets acquired and liabilities assumed at their acquisition date fair values. Goodwill is measured as the excess of consideration transferred over the acquisition date net fair values of the assets acquired and the liabilities assumed. The purchase price allocation is a critical accounting policy because the estimation of fair values of acquired assets and assumed liabilities is judgmental and requires various assumptions. Further, the amounts and useful lives assigned to depreciable and amortizable assets versus amounts assigned to goodwill, which is not amortized, can significantly affect the results of operations in the period of and for periods subsequent to a business combination.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
AddedMD&A
Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction, and therefore represents an exit price. When identifiable intangible assets, are acquired, we determine the fair values of the assets as of the acquisition date. An income approach, which generally relies upon projected cash flow models, is used in estimating the fair value of the acquired intangible assets. These cash flow projections are based on management's estimates of economic and market conditions including: the estimated future cash flows from revenues of acquired assets; the timing and projection of costs and expenses, discount rates; and tax rates.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RemovedMD&A
SPN-820 is a first-in-class, orally active small molecule that increases the brain mechanistic target of rapamycin complex 1 (mTORC1) mediated synaptic function intracellularly. SPN-820 does not bind to or modulate any cell surface receptors and therefore is unlikely to have abuse potential given lack of binding to targets implicated in drug abuse. In addition, unlike leucine, it is not incorporated into proteins during protein synthesis, and therefore, it is more available at the target site in the brain than leucine.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•The FDA has approved an update for the label for Qelbree to include new pharmacodynamic data. The updated label highlights Qelbree’s partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, reinforcing its multimodal pharmacodynamic profile. Additionally, the updated label now includes new
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
lactation data for breastfeeding women with attention-deficit/hyperactivity disorder (ADHD), showing that the transfer of Qelbree into breastmilk is low.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•The Company recently presented interim results from an open-label Phase IV trial with Qelbree in 161 adults with ADHD and mood symptoms at the 30th Annual National Psychopharmacology Update™ conference. The improvements in clinician and patient-rated measures of ADHD, depression and anxiety symptoms in the interim data analysis, analyzed for the first 95 patients who completed the trial, are encouraging and suggest that Qelbree's effects may extend to adults with complex ADHD. Efficacy and safety outcomes were consistent with the double-blind, pivotal trial of Qelbree in adult ADHD. Topline results from the full Phase IV trial (all 161 adults) are consistent with the interim results and will be presented at the American Psychiatric Association Annual Meeting in May 2025.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•Total IQVIA prescriptions for Qelbree were 767,791 for full year 2024, an increase of 25% compared to full year 2023.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•The Company received a two-plus year patent term extension from the US Patent and Trademark Office for US Patent number 9,662,338 that covers Qelbree. This extends the original expiration date of the patent to the year 2035.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
ONAPGO (formerly SPN-830) (apomorphine infusion device) for treatment of Parkinson's disease (PD)
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•In November 2024, the Company reported topline results from an open label Phase 2a study in patients with treatment-resistant seizures. The study suggested a differentiated profile, with strong efficacy in focal seizures at the 3mg to 4mg twice daily doses. SPN-817 was safe and had acceptable tolerability with two subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenance period.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
•The Company completed a Phase 1 pharmacokinetic study of two oral formulations in healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
from the date of sale and the time at which we issue credit for expired products. We had favorable actual returns in 2024 for
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
Qelbree and as a result, the Company changed its estimated provision for Qelbree product returns based on the most recent
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RemovedMD&A
accruals and record adjustments when rebate trends, rebate programs and contract terms, legislative changes, or other significant events indicate that a change in reserve is appropriate. Historically, adjustments to rebate accruals have not been material to net earnings.
Read it in 10-K Feb 25, 2025 at sec.govopen_in_new
RewordedMD&A
Year Ended December 31, Change 2025 2024 2023 Amount Percent Net product sales Qelbree $ 304,654 $ 241,273 $ 140,192 $ 101,081 72% 63,381 26% GOCOVRI 146,824 130,824 119,637 11,187 9% 16,000 12% Oxtellar XR 40,700 99,464 113,404 (13,940) (12)% (58,764) (59)% APOKYN 47,771 73,926 75,083 (1,157) (2)% (26,155) (35)% Trokendi XR 42,421 63,201 94,336 (31,135) (20,780) (33)% ONAPGO 17,254 — 17,254 100% Other(1) 26,912 29,008 31,281 (2,273) (2,096) (7)% Total net product sales $ 626,536 $ 637,696 $ 573,933 $ 63,763 11% (11,160) (2)% Collaboration revenue (ZURZUVAE) 52,996 — 52,996 100% Royalty, licensing licensing, and other revenues 39,420 24,121 33,588 (9,467) (28)% 15,299 63% Total revenues $ 718,952 $ 661,817 $ 607,521 $ 54,296 57,135 9%
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The following table provides the components of other income (expense) during the years indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Interest income & and other income, net $13,253 $16,204 $ 16,204 (2,951) (18)% Total $13,253 $16,204 $ 10,453 $ 5,751 55% Interest expense — (1,321) 1,321 (100)% Noncash interest expense on nonrecourse liability related to sale of future royalties — (562) 562 (100)% Noncash interest expense on debt — (532) 532 (100)% Total $ 16,204 $ 8,038 $ 8,166 102% (2,951) (18)%
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
While we expect continued profitability in future years, we anticipate there may be significant variability from year to year in the level of our profits particularly due to continued market and payor pressures for our commercial products; the unfavorable impact of the loss of patent exclusivity for Trokendi XR in January 2023 and Oxtellar XR in September 2024; the potential unfavorable impact of the forthcoming loss of exclusivity of XADAGO; funding for research and development of our product candidates; and the additional funding to for the launch ONAPGO (apomorphine hydrochloride) injection, formerly known as SPN-830, of ONAPGO, which was approved by the FDA in February 2025 and launched in April 2025, and the additional funding for the marketing of ZURZUVAE which was acquired as part of the Sage Acquisition in July 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The increase decrease in cash flows provided by operating activities was primarily due to higher the decrease in net income earnings for the year ended December 31, 2024 compared to the same period in prior year, and 2025 as well as changes in working capital which reflects the timing impacts of cash collections on receivables and settlement of payables. capital.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
If the carrying amount of the asset exceeds its fair value, the Company writes down the asset to its estimated fair value, and an impairment loss equal to the difference between the assets fair value and carrying value is recognized in the consolidated statement of earnings (loss) in the period at which such determination is made.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
Cash and cash equivalents, marketable securities, and marketable securities restricted cash are as follows comprised of the following (dollars in thousands):December 31, 2024 2025 December 31, 2023 2024 Cash and cash equivalents $ 128,448 $ 69,331 $ 75,054 Marketable securities 180,222 384,281 179,820 Long-term marketable securities Restricted cash 1,450 — 16,617 Total $ 310,120 $ 453,612 $ 271,491
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The table below provides information regarding our selling, Selling, general, and administrative (SG&A) expenses for the years indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Selling and marketing expense $ 227,293 $229,186 288,651 $227,293 $ (1,893) (1)% 61,358 27% General and administrative expense 196,912 94,289 107,175 (12,886) (12)% 102,623 109% Total $ 321,582 $336,361 485,563 $321,582 $ (14,779) (4)% 163,981 51%
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The provision for sales discounts increased from $65.9 million in 2023 to $69.5 million in 2024 to $73.0 million in 2025 primarily attributable to new product launched in 2025 and higher net product Qelbree sales in 2024 2025 compared to 2023. 2024.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
This decrease was primarily due to $11.9 a decrease of $20.7 million of adjustments in the estimated provision for product returns related to prior year sales offset by higher net product sales and timing of related return activity. sales.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The Company is actively monitoring returns activity in light of the timeline loss of exclusivity and actual and possible further future sales decline based on timing of generic entry.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The accrued product returns balance decreased from $57.3 million as of December 31, 2023 to $53.4 million as of December 31, 2024. 2024 to $37.8 million as of December 31, 2025.
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new
RewordedMD&A
The following table provides information regarding the contingent Contingent consideration gain loss (gain) during the periods indicated (dollars in thousands):Year Ended December 31, Change 2025 2024 2023 Amount Percent Contingent consideration gain loss (gain) $ 25,419 $ (6,110) $ (1,517) $ (4,593) 303% 31,529 (516)%
Read it in 10-K Mar 2, 2026 at sec.govopen_in_new